Research programme: fatty acid amide hydrolase inhibitors - Adolor CorporationAlternative Names: OL-135
Latest Information Update: 11 Mar 2009
At a glance
- Originator Adolor Corporation
- Class Small molecules
- Mechanism of Action Fatty acid amide hydrolase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammatory pain
Most Recent Events
- 07 Nov 2007 Preclinical trials in Inflammatory pain in USA (PO)